{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:10:25Z","timestamp":1791385825367,"version":"4.3.3"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,21]],"date-time":"2021-03-21T00:00:00Z","timestamp":1616284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,21]],"date-time":"2021-03-21T00:00:00Z","timestamp":1616284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["108-2119-M-001-016"],"award-info":[{"award-number":["108-2119-M-001-016"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["109-2321-B-002-033"],"award-info":[{"award-number":["109-2321-B-002-033"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001869","name":"Academia Sinica","doi-asserted-by":"publisher","award":["AS-CDA-105-L06"],"award-info":[{"award-number":["AS-CDA-105-L06"]}],"id":[{"id":"10.13039\/501100001869","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s13346-021-00965-y","type":"journal-article","created":{"date-parts":[[2021,3,21]],"date-time":"2021-03-21T19:02:25Z","timestamp":1616353345000},"page":"1420-1437","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Nanotechnology advances in pathogen- and host-targeted antiviral delivery: multipronged therapeutic intervention for pandemic control"],"prefix":"10.1007","volume":"11","author":[{"given":"Kai-Chieh","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Chen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiao-Han","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Yao","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0988-7029","authenticated-orcid":false,"given":"Che-Ming Jack","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,21]]},"reference":[{"key":"965_CR1","unstructured":"Taxonomic. International Committee on Taxonomy of Viruses (ICTV). 2020. https:\/\/talk.ictvonline.org\/taxonomy\/"},{"issue":"6","key":"965_CR2","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.tim.2005.04.003","volume":"13","author":"M Breitbart","year":"2005","unstructured":"Breitbart M, Rohwer F. Here a virus, there a virus, everywhere the same virus? Trends Microbiol. 2005;13(6):278\u201384. https:\/\/doi.org\/10.1016\/j.tim.2005.04.003.","journal-title":"Trends Microbiol"},{"issue":"68","key":"965_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.rmu.2015.05.003","volume":"17","author":"OL Bryan-Marrugo","year":"2015","unstructured":"Bryan-Marrugo OL, Ramos-Jim\u00e9nez J, Barrera-Salda\u00f1a H, Rojas-Mart\u00ednez A, Vidaltamayo R, Rivas-Estilla AM. History and progress of antiviral drugs: from acyclovir to direct-acting antiviral agents (DAAs) for Hepatitis C. Medicina Universitaria. 2015;17(68):165\u201374. https:\/\/doi.org\/10.1016\/j.rmu.2015.05.003.","journal-title":"Medicina Universitaria"},{"key":"965_CR4","doi-asserted-by":"publisher","unstructured":"Rodriguez Mega E. COVID has killed more than one million people. How many more will die? Nature. 2020. https:\/\/doi.org\/10.1038\/d41586-020-02762-y.","DOI":"10.1038\/d41586-020-02762-y"},{"key":"965_CR5","unstructured":"Organization WH. \u201cSolidarity\u201d clinical trial for COVID-19 treatments. 2020."},{"issue":"14","key":"965_CR6","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1212\/WNL.0b013e31824e8f0d","volume":"78","author":"G Hubsher","year":"2012","unstructured":"Hubsher G, Haider M, Okun MS. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology. 2012;78(14):1096\u20139. https:\/\/doi.org\/10.1212\/WNL.0b013e31824e8f0d.","journal-title":"Neurology"},{"issue":"19","key":"965_CR7","doi-asserted-by":"publisher","first-page":"e2000979","DOI":"10.1002\/adhm.202000979","volume":"9","author":"E Ruiz-Hitzky","year":"2020","unstructured":"Ruiz-Hitzky E, Darder M, Wicklein B, Ruiz-Garcia C, Martin-Sampedro R, Del Real G, et al. Nanotechnology responses to COVID-19. Adv Healthc Mater. 2020;9(19):e2000979. https:\/\/doi.org\/10.1002\/adhm.202000979.","journal-title":"Adv Healthc Mater"},{"issue":"8","key":"965_CR8","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/s41565-020-0751-0","volume":"15","author":"S Talebian","year":"2020","unstructured":"Talebian S, Wallace GG, Schroeder A, Stellacci F, Conde J. Nanotechnology-based disinfectants and sensors for SARS-CoV-2. Nat Nanotechnol. 2020;15(8):618\u201321. https:\/\/doi.org\/10.1038\/s41565-020-0751-0.","journal-title":"Nat Nanotechnol"},{"issue":"10","key":"965_CR9","doi-asserted-by":"publisher","first-page":"12522","DOI":"10.1021\/acsnano.0c07197","volume":"14","author":"YH Chung","year":"2020","unstructured":"Chung YH, Beiss V, Fiering SN, Steinmetz NF. COVID-19 vaccine frontrunners and their nanotechnology design. ACS Nano. 2020;14(10):12522\u201337. https:\/\/doi.org\/10.1021\/acsnano.0c07197.","journal-title":"ACS Nano"},{"key":"965_CR10","doi-asserted-by":"publisher","unstructured":"Tang Z, Kong N, Zhang X, Liu Y, Hu P, Mou S et al. A materials-science perspective on tackling COVID-19. Nat Rev Mater. 2020:1\u201314. https:\/\/doi.org\/10.1038\/s41578-020-00247-y","DOI":"10.1038\/s41578-020-00247-y"},{"key":"965_CR11","doi-asserted-by":"publisher","first-page":"101031","DOI":"10.1016\/j.nantod.2020.101031","volume":"36","author":"J Zhou","year":"2021","unstructured":"Zhou J, Krishnan N, Jiang Y, Fang RH, Zhang L. Nanotechnology for virus treatment. Nano Today. 2021;36:101031. https:\/\/doi.org\/10.1016\/j.nantod.2020.101031.","journal-title":"Nano Today"},{"key":"965_CR12","doi-asserted-by":"publisher","unstructured":"Let\u2019s talk about lipid nanoparticles. Nat Rev Mater. 2021;6(2):99-. https:\/\/doi.org\/10.1038\/s41578-021-00281-4","DOI":"10.1038\/s41578-021-00281-4"},{"key":"965_CR13","first-page":"467","volume-title":"Melero JA","author":"V M\u00e1s","year":"2013","unstructured":"M\u00e1s V. Melero JA. Entry of Enveloped Viruses into Host Cells: Membrane fusion. Structure and Physics of viruses. Subcellular Biochemistry; 2013. p. 467\u201387."},{"issue":"1","key":"965_CR14","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1038\/s41467-020-18319-6","volume":"11","author":"J Yang","year":"2020","unstructured":"Yang J, Petitjean SJL, Koehler M, Zhang Q, Dumitru AC, Chen W, et al. Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor. Nat Commun. 2020;11(1):4541. https:\/\/doi.org\/10.1038\/s41467-020-18319-6.","journal-title":"Nat Commun"},{"issue":"7\u20138","key":"965_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10354-016-0461-2","volume":"166","author":"D Blaas","year":"2016","unstructured":"Blaas D. Viral entry pathways: the example of common cold viruses. Wien Med Wochenschr. 2016;166(7\u20138):211\u201326. https:\/\/doi.org\/10.1007\/s10354-016-0461-2.","journal-title":"Wien Med Wochenschr"},{"issue":"6492","key":"965_CR16","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1126\/science.abb7498","volume":"368","author":"Y Gao","year":"2020","unstructured":"Gao Y, Yan L, Huang Y, Liu F, Zhao Y, Cao L, et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science. 2020;368(6492):779\u201382. https:\/\/doi.org\/10.1126\/science.abb7498.","journal-title":"Science"},{"issue":"6498","key":"965_CR17","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1126\/science.abc1560","volume":"368","author":"W Yin","year":"2020","unstructured":"Yin W, Mao C, Luan X, Shen DD, Shen Q, Su H, et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science. 2020;368(6498):1499\u2013504. https:\/\/doi.org\/10.1126\/science.abc1560.","journal-title":"Science"},{"issue":"1","key":"965_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/s0168-1702(01)00266-0","volume":"77","author":"S Barman","year":"2001","unstructured":"Barman S, Ali A, Hui EK, Adhikary L, Nayak DP. Transport of viral proteins to the apical membranes and interaction of matrix protein with glycoproteins in the assembly of influenza viruses. Virus Res. 2001;77(1):61\u20139. https:\/\/doi.org\/10.1016\/s0168-1702(01)00266-0.","journal-title":"Virus Res"},{"issue":"5","key":"965_CR19","first-page":"431","volume":"45","author":"JR Jacob","year":"2007","unstructured":"Jacob JR, Mansfield K, You JE, Tennant BC, Kim YH. Natural iminosugar derivatives of 1-deoxynojirimycin inhibit glycosylation of hepatitis viral envelope proteins. J Microbiol. 2007;45(5):431\u201340.","journal-title":"J Microbiol"},{"issue":"5","key":"965_CR20","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","volume":"6","author":"RT Eastman","year":"2020","unstructured":"Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, et al. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent Sci. 2020;6(5):672\u201383. https:\/\/doi.org\/10.1021\/acscentsci.0c00489.","journal-title":"ACS Cent Sci"},{"key":"965_CR21","doi-asserted-by":"crossref","unstructured":"Milovanovic M, Arsenijevic A, Milovanovic J, Kanjevac T, Arsenijevic N. Nanoparticles in antiviral therapy. In: Grumezescu AM, editor. Antimicrobial Nanoarchitectonics. Elsevier; 2017. p. 383\u2013410.","DOI":"10.1016\/B978-0-323-52733-0.00014-8"},{"issue":"2","key":"965_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3851\/IMP1684","volume":"21","author":"D Lembo","year":"2010","unstructured":"Lembo D, Cavalli R. Nanoparticulate delivery systems for antiviral drugs. Antivir Chem Chemother. 2010;21(2):53\u201370. https:\/\/doi.org\/10.3851\/IMP1684.","journal-title":"Antivir Chem Chemother"},{"issue":"4","key":"965_CR23","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1177\/2049936117713593","volume":"4","author":"L Singh","year":"2017","unstructured":"Singh L, Kruger HG, Maguire GEM, Govender T, Parboosing R. The role of nanotechnology in the treatment of viral infections. Ther Adv Infect Dis. 2017;4(4):105\u201331. https:\/\/doi.org\/10.1177\/2049936117713593.","journal-title":"Ther Adv Infect Dis"},{"key":"965_CR24","doi-asserted-by":"publisher","unstructured":"Nasrollahzadeh M, Sajjadi M, Soufi GJ, Iravani S, Varma RS. Nanomaterials and nanotechnology-associated innovations against viral infections with a focus on coronaviruses. Nanomaterials (Basel). 2020;10(6). https:\/\/doi.org\/10.3390\/nano10061072.","DOI":"10.3390\/nano10061072"},{"key":"965_CR25","doi-asserted-by":"publisher","unstructured":"Gurunathan S, Qasim M, Choi Y, Do JT, Park C, Hong K et al. Antiviral potential of nanoparticles\u2014can nanoparticles fight against coronaviruses? Nanomaterials (Basel). 2020;10(9). https:\/\/doi.org\/10.3390\/nano10091645.","DOI":"10.3390\/nano10091645"},{"issue":"1\u20132","key":"965_CR26","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.ijpharm.2012.07.070","volume":"436","author":"D Belletti","year":"2012","unstructured":"Belletti D, Tosi G, Forni F, Gamberini MC, Baraldi C, Vandelli MA, et al. Chemico-physical investigation of tenofovir loaded polymeric nanoparticles. Int J Pharm. 2012;436(1\u20132):753\u201363. https:\/\/doi.org\/10.1016\/j.ijpharm.2012.07.070.","journal-title":"Int J Pharm"},{"key":"965_CR27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.biomaterials.2014.11.012","volume":"41","author":"P Puligujja","year":"2015","unstructured":"Puligujja P, Balkundi SS, Kendrick LM, Baldridge HM, Hilaire JR, Bade AN, et al. Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations. Biomaterials. 2015;41:141\u201350. https:\/\/doi.org\/10.1016\/j.biomaterials.2014.11.012.","journal-title":"Biomaterials"},{"key":"965_CR28","doi-asserted-by":"publisher","unstructured":"Mandal S, Belshan M, Holec A, Zhou Y, Destache CJ. An Enhanced emtricitabine-loaded long-acting nanoformulation for prevention or treatment of HIV infection. Antimicrob Agents Chemother. 2017;61(1). https:\/\/doi.org\/10.1128\/AAC.01475-16.","DOI":"10.1128\/AAC.01475-16"},{"key":"965_CR29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.antiviral.2019.04.007","volume":"167","author":"S Mandal","year":"2019","unstructured":"Mandal S, Prathipati PK, Belshan M, Destache CJ. A potential long-acting bictegravir loaded nano-drug delivery system for HIV-1 infection: a proof-of-concept study. Antiviral Res. 2019;167:83\u20138. https:\/\/doi.org\/10.1016\/j.antiviral.2019.04.007.","journal-title":"Antiviral Res"},{"issue":"2","key":"965_CR30","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/s0005-2736(01)00432-1","volume":"1558","author":"JF Gagne","year":"2002","unstructured":"Gagne JF, Desormeaux A, Perron S, Tremblay MJ, Bergeron MG. Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes. Biochim Biophys Acta. 2002;1558(2):198\u2013210. https:\/\/doi.org\/10.1016\/s0005-2736(01)00432-1.","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"965_CR31","doi-asserted-by":"publisher","first-page":"897","DOI":"10.35333\/jrp.2019.37","volume":"23","author":"AA \u00d6Zt\u00dcRk","year":"2019","unstructured":"\u00d6Zt\u00dcRk AA, Kirimlio\u011eLu GY. Preparation and in vitro characterization of lamivudine loaded nanoparticles prepared by acid and\/or ester terminated PLGA for effective oral anti-retroviral therapy. Journal of Research in Pharmacy. 2019;23(5):897\u2013913. https:\/\/doi.org\/10.35333\/jrp.2019.37.","journal-title":"Journal of Research in Pharmacy"},{"issue":"6","key":"965_CR32","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1007\/s11095-011-0622-3","volume":"29","author":"J das Neves","year":"2011","unstructured":"das Neves J, Michiels J, Ari\u00ebn KK, Vanham G, Amiji M, Bahia MF, et al. Polymeric Nanoparticles Affect the Intracellular Delivery, Antiretroviral Activity and Cytotoxicity of the Microbicide Drug Candidate Dapivirine. Pharm Res. 2011;29(6):1468\u201384. https:\/\/doi.org\/10.1007\/s11095-011-0622-3.","journal-title":"Pharm Res"},{"key":"965_CR33","doi-asserted-by":"publisher","unstructured":"Gong Y, Zhi K, Nagesh PKB, Sinha N, Chowdhury P, Chen H et al. An elvitegravir nanoformulation crosses the blood-brain barrier and suppresses HIV-1 replication in microglia. Viruses. 2020;12(5). https:\/\/doi.org\/10.3390\/v12050564","DOI":"10.3390\/v12050564"},{"issue":"2","key":"965_CR34","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.antiviral.2009.08.003","volume":"84","author":"R Clayton","year":"2009","unstructured":"Clayton R, Ohagen A, Nicol F, Del Vecchio AM, Jonckers TH, Goethals O, et al. Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes. Antiviral Res. 2009;84(2):142\u20139. https:\/\/doi.org\/10.1016\/j.antiviral.2009.08.003.","journal-title":"Antiviral Res"},{"issue":"1","key":"965_CR35","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1186\/s11671-015-1112-z","volume":"10","author":"X Tang","year":"2015","unstructured":"Tang X, Liang Y, Liu X, Zhou S, Liu L, Zhang F, et al. PLGA-PEG nanoparticles coated with anti-CD45RO and loaded with HDAC plus protease inhibitors activate latent HIV and inhibit viral spread. Nanoscale Res Lett. 2015;10(1):413. https:\/\/doi.org\/10.1186\/s11671-015-1112-z.","journal-title":"Nanoscale Res Lett"},{"key":"965_CR36","doi-asserted-by":"publisher","first-page":"119084","DOI":"10.1016\/j.ijpharm.2020.119084","volume":"577","author":"R Asasutjarit","year":"2020","unstructured":"Asasutjarit R, Managit C, Phanaksri T, Treesuppharat W, Fuongfuchat A. Formulation development and in vitro evaluation of transferrin-conjugated liposomes as a carrier of ganciclovir targeting the retina. Int J Pharm. 2020;577:119084. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119084.","journal-title":"Int J Pharm"},{"key":"965_CR37","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.antiviral.2018.06.005","volume":"156","author":"S Mandal","year":"2018","unstructured":"Mandal S, Kang G, Prathipati PK, Fan W, Li Q, Destache CJ. Long-acting parenteral combination antiretroviral loaded nano-drug delivery system to treat chronic HIV-1 infection: a humanized mouse model study. Antiviral Res. 2018;156:85\u201391. https:\/\/doi.org\/10.1016\/j.antiviral.2018.06.005.","journal-title":"Antiviral Res"},{"issue":"2","key":"965_CR38","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s11095-016-2048-4","volume":"34","author":"P Kumar","year":"2017","unstructured":"Kumar P, Lakshmi YS, Kondapi AK. Triple drug combination of zidovudine, efavirenz and lamivudine loaded lactoferrin nanoparticles: an effective nano first-line regimen for HIV therapy. Pharm Res. 2017;34(2):257\u201368. https:\/\/doi.org\/10.1007\/s11095-016-2048-4.","journal-title":"Pharm Res"},{"issue":"8","key":"965_CR39","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1002\/jps.24046","volume":"103","author":"J Duan","year":"2014","unstructured":"Duan J, Freeling JP, Koehn J, Shu C, Ho RJ. Evaluation of atazanavir and darunavir interactions with lipids for developing pH-responsive anti-HIV drug combination nanoparticles. J Pharm Sci. 2014;103(8):2520\u20139. https:\/\/doi.org\/10.1002\/jps.24046.","journal-title":"J Pharm Sci"},{"issue":"1","key":"965_CR40","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1089\/aid.2014.0210","volume":"31","author":"JP Freeling","year":"2015","unstructured":"Freeling JP, Koehn J, Shu C, Sun J, Ho RJ. Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates. AIDS Res Hum Retroviruses. 2015;31(1):107\u201314. https:\/\/doi.org\/10.1089\/aid.2014.0210.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"965_CR41","doi-asserted-by":"publisher","first-page":"8579","DOI":"10.2147\/IJN.S185806","volume":"13","author":"CJ Hu","year":"2018","unstructured":"Hu CJ, Chen YT, Fang ZS, Chang WS, Chen HW. Antiviral efficacy of nanoparticulate vacuolar ATPase inhibitors against influenza virus infection. Int J Nanomedicine. 2018;13:8579\u201393. https:\/\/doi.org\/10.2147\/IJN.S185806.","journal-title":"Int J Nanomedicine"},{"issue":"2","key":"965_CR42","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/mt.2009.271","volume":"18","author":"SS Kim","year":"2010","unstructured":"Kim SS, Peer D, Kumar P, Subramanya S, Wu H, Asthana D, et al. RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther. 2010;18(2):370\u20136. https:\/\/doi.org\/10.1038\/mt.2009.271.","journal-title":"Mol Ther"},{"issue":"7552","key":"965_CR43","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nature14442","volume":"521","author":"EP Thi","year":"2015","unstructured":"Thi EP, Mire CE, Lee AC, Geisbert JB, Zhou JZ, Agans KN, et al. Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. Nature. 2015;521(7552):362\u20135. https:\/\/doi.org\/10.1038\/nature14442.","journal-title":"Nature"},{"issue":"1\u20132","key":"965_CR44","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ijpharm.2010.08.026","volume":"400","author":"J Wang","year":"2010","unstructured":"Wang J, Feng SS, Wang S, Chen ZY. Evaluation of cationic nanoparticles of biodegradable copolymers as siRNA delivery system for hepatitis B treatment. Int J Pharm. 2010;400(1\u20132):194\u2013200. https:\/\/doi.org\/10.1016\/j.ijpharm.2010.08.026.","journal-title":"Int J Pharm"},{"issue":"3","key":"965_CR45","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jhep.2008.10.029","volume":"50","author":"SI Kim","year":"2009","unstructured":"Kim SI, Shin D, Lee H, Ahn BY, Yoon Y, Kim M. Targeted delivery of siRNA against hepatitis C virus by apolipoprotein A-I-bound cationic liposomes. J Hepatol. 2009;50(3):479\u201388. https:\/\/doi.org\/10.1016\/j.jhep.2008.10.029.","journal-title":"J Hepatol"},{"issue":"1","key":"965_CR46","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jconrel.2012.06.008","volume":"162","author":"JM Steinbach","year":"2012","unstructured":"Steinbach JM, Weller CE, Booth CJ, Saltzman WM. Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection. J Control Release. 2012;162(1):102\u201310. https:\/\/doi.org\/10.1016\/j.jconrel.2012.06.008.","journal-title":"J Control Release"},{"issue":"8","key":"965_CR47","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/s41563-020-0674-z","volume":"19","author":"TA Kulkarni","year":"2020","unstructured":"Kulkarni TA, Bade AN, Sillman B, Shetty BLD, Wojtkiewicz MS, Gautam N, et al. A year-long extended release nanoformulated cabotegravir prodrug. Nat Mater. 2020;19(8):910\u201320. https:\/\/doi.org\/10.1038\/s41563-020-0674-z.","journal-title":"Nat Mater"},{"issue":"6","key":"965_CR48","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1007\/s11095-011-0622-3","volume":"29","author":"J das Neves","year":"2012","unstructured":"das Neves J, Michiels J, Arien KK, Vanham G, Amiji M, Bahia MF, et al. Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine. Pharm Res. 2012;29(6):1468\u201384. https:\/\/doi.org\/10.1007\/s11095-011-0622-3.","journal-title":"Pharm Res."},{"issue":"8","key":"965_CR49","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2217\/nnm.09.71","volume":"4","author":"AS Nowacek","year":"2009","unstructured":"Nowacek AS, Miller RL, McMillan J, Kanmogne G, Kanmogne M, Mosley RL, et al. NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomedicine (Lond). 2009;4(8):903\u201317. https:\/\/doi.org\/10.2217\/nnm.09.71.","journal-title":"Nanomedicine (Lond)"},{"issue":"17","key":"965_CR50","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1097\/QAD.0b013e328357f5ad","volume":"26","author":"PK Dash","year":"2012","unstructured":"Dash PK, Gendelman HE, Roy U, Balkundi S, Alnouti Y, Mosley RL, et al. Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. AIDS. 2012;26(17):2135\u201344. https:\/\/doi.org\/10.1097\/QAD.0b013e328357f5ad.","journal-title":"AIDS"},{"issue":"1","key":"965_CR51","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1038\/s41467-019-09354-z","volume":"10","author":"JJ Hobson","year":"2019","unstructured":"Hobson JJ, Al-Khouja A, Curley P, Meyers D, Flexner C, Siccardi M, et al. Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies. Nat Commun. 2019;10(1):1413. https:\/\/doi.org\/10.1038\/s41467-019-09354-z.","journal-title":"Nat Commun"},{"issue":"5","key":"965_CR52","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jinf.2020.06.073","volume":"81","author":"M Gousseff","year":"2020","unstructured":"Gousseff M, Penot P, Gallay L, Batisse D, Benech N, Bouiller K, et al. Clinical recurrences of COVID-19 symptoms after recovery: viral relapse, reinfection or inflammatory rebound? J Infect. 2020;81(5):816\u201346. https:\/\/doi.org\/10.1016\/j.jinf.2020.06.073.","journal-title":"J Infect"},{"issue":"3","key":"965_CR53","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.ejpb.2007.07.005","volume":"68","author":"M Feng","year":"2008","unstructured":"Feng M, Cai Q, Huang H, Zhou P. Liver targeting and anti-HBV activity of reconstituted HDL-acyclovir palmitate complex. Eur J Pharm Biopharm. 2008;68(3):688\u201393. https:\/\/doi.org\/10.1016\/j.ejpb.2007.07.005.","journal-title":"Eur J Pharm Biopharm"},{"issue":"8","key":"965_CR54","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.addr.2007.11.006","volume":"60","author":"S Azarmi","year":"2008","unstructured":"Azarmi S, Roa WH, Lobenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev. 2008;60(8):863\u201375. https:\/\/doi.org\/10.1016\/j.addr.2007.11.006.","journal-title":"Adv Drug Deliv Rev"},{"key":"965_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-020-00644-2","author":"Z Zhao","year":"2020","unstructured":"Zhao Z, Ukidve A, Krishnan V, Fehnel A, Pan DC, Gao Y, et al. Systemic tumour suppression via the preferential accumulation of erythrocyte-anchored chemokine-encapsulating nanoparticles in lung metastases. Nat Biomed Eng. 2020. https:\/\/doi.org\/10.1038\/s41551-020-00644-2.","journal-title":"Nat Biomed Eng"},{"issue":"18","key":"965_CR56","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1001\/jama.2020.3786","volume":"323","author":"W Wang","year":"2020","unstructured":"Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323(18):1843\u20134. https:\/\/doi.org\/10.1001\/jama.2020.3786.","journal-title":"JAMA"},{"issue":"10238","key":"965_CR57","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","volume":"395","author":"IF Hung","year":"2020","unstructured":"Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395(10238):1695\u2013704. https:\/\/doi.org\/10.1016\/S0140-6736(20)31042-4.","journal-title":"Lancet"},{"issue":"6629","key":"965_CR58","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/387188a0","volume":"387","author":"AS Perelson","year":"1997","unstructured":"Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997;387(6629):188\u201391. https:\/\/doi.org\/10.1038\/387188a0.","journal-title":"Nature"},{"issue":"21","key":"965_CR59","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1056\/NEJM199905273402101","volume":"340","author":"L Zhang","year":"1999","unstructured":"Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999;340(21):1605\u201313. https:\/\/doi.org\/10.1056\/NEJM199905273402101.","journal-title":"N Engl J Med"},{"issue":"5","key":"965_CR60","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1089\/AID.2012.0301","volume":"29","author":"A Shibata","year":"2013","unstructured":"Shibata A, McMullen E, Pham A, Belshan M, Sanford B, Zhou Y, et al. Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment. AIDS Res Hum Retroviruses. 2013;29(5):746\u201354. https:\/\/doi.org\/10.1089\/AID.2012.0301.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"20","key":"965_CR61","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","volume":"383","author":"LA Jackson","year":"2020","unstructured":"Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA vaccine against SARS-CoV-2\u2014preliminary report. N Engl J Med. 2020;383(20):1920\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2022483.","journal-title":"N Engl J Med"},{"issue":"7830","key":"965_CR62","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","volume":"586","author":"MJ Mulligan","year":"2020","unstructured":"Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589\u201393. https:\/\/doi.org\/10.1038\/s41586-020-2639-4.","journal-title":"Nature"},{"key":"965_CR63","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.3389\/fmicb.2018.02151","volume":"9","author":"A Levanova","year":"2018","unstructured":"Levanova A, Poranen MM. RNA interference as a prospective tool for the control of human viral infections. Front Microbiol. 2018;9:2151. https:\/\/doi.org\/10.3389\/fmicb.2018.02151.","journal-title":"Front Microbiol"},{"issue":"11","key":"965_CR64","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nmat3765","volume":"12","author":"R Kanasty","year":"2013","unstructured":"Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat Mater. 2013;12(11):967\u201377. https:\/\/doi.org\/10.1038\/nmat3765.","journal-title":"Nat Mater"},{"key":"965_CR65","doi-asserted-by":"publisher","unstructured":"Zhang W, Yang H, Kong X, Mohapatra S, Juan-Vergara HS, Hellermann G et al. Erratum: inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med. 2005;11(2):233-. https:\/\/doi.org\/10.1038\/nm0205-233b","DOI":"10.1038\/nm0205-233b"},{"issue":"1","key":"965_CR66","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s13346-017-0426-z","volume":"8","author":"A Jamali","year":"2018","unstructured":"Jamali A, Mottaghitalab F, Abdoli A, Dinarvand M, Esmailie A, Kheiri MT, et al. Inhibiting influenza virus replication and inducing protection against lethal influenza virus challenge through chitosan nanoparticles loaded by siRNA. Drug Deliv Transl Res. 2018;8(1):12\u201320. https:\/\/doi.org\/10.1007\/s13346-017-0426-z.","journal-title":"Drug Deliv Transl Res"},{"issue":"5","key":"965_CR67","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1002\/med.21664","volume":"40","author":"X Ji","year":"2020","unstructured":"Ji X, Li Z. Medicinal chemistry strategies toward host targeting antiviral agents. Med Res Rev. 2020;40(5):1519\u201357. https:\/\/doi.org\/10.1002\/med.21664.","journal-title":"Med Res Rev"},{"key":"965_CR68","doi-asserted-by":"publisher","unstructured":"Staring J, Raaben M, Brummelkamp TR. Viral escape from endosomes and host detection at a glance. J Cell Sci. 2018;131(15). https:\/\/doi.org\/10.1242\/jcs.216259.","DOI":"10.1242\/jcs.216259"},{"issue":"4","key":"965_CR69","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1128\/CMR.14.4.778-809.2001","volume":"14","author":"CE Samuel","year":"2001","unstructured":"Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev. 2001;14(4):778\u2013809. https:\/\/doi.org\/10.1128\/CMR.14.4.778-809.2001 (table of contents).","journal-title":"Clin Microbiol Rev."},{"issue":"1","key":"965_CR70","doi-asserted-by":"publisher","first-page":"e00293","DOI":"10.1002\/prp2.293","volume":"5","author":"MAA Al-Bari","year":"2017","unstructured":"Al-Bari MAA. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharmacol Res Perspect. 2017;5(1):e00293. https:\/\/doi.org\/10.1002\/prp2.293.","journal-title":"Pharmacol Res Perspect"},{"issue":"4","key":"965_CR71","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41565-020-0674-9","volume":"15","author":"TY Hu","year":"2020","unstructured":"Hu TY, Frieman M, Wolfram J. Insights from nanomedicine into chloroquine efficacy against COVID-19. Nat Nanotechnol. 2020;15(4):247\u20139. https:\/\/doi.org\/10.1038\/s41565-020-0674-9.","journal-title":"Nat Nanotechnol"},{"issue":"10","key":"965_CR72","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.7150\/ijbs.45498","volume":"16","author":"N Yang","year":"2020","unstructured":"Yang N, Shen HM. Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19. Int J Biol Sci. 2020;16(10):1724\u201331. https:\/\/doi.org\/10.7150\/ijbs.45498.","journal-title":"Int J Biol Sci"},{"issue":"7798","key":"965_CR73","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"F Wu","year":"2020","unstructured":"Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265\u20139. https:\/\/doi.org\/10.1038\/s41586-020-2008-3.","journal-title":"Nature"},{"issue":"1","key":"965_CR74","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.1038\/s41467-020-17986-9","volume":"11","author":"H Zhao","year":"2020","unstructured":"Zhao H, To KKW, Sze KH, Yung TT, Bian M, Lam H, et al. A broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2. Nat Commun. 2020;11(1):4252. https:\/\/doi.org\/10.1038\/s41467-020-17986-9.","journal-title":"Nat Commun"},{"issue":"1","key":"965_CR75","doi-asserted-by":"publisher","first-page":"13738","DOI":"10.1038\/s41598-017-14221-2","volume":"7","author":"J Wolfram","year":"2017","unstructured":"Wolfram J, Nizzero S, Liu H, Li F, Zhang G, Li Z, et al. A chloroquine-induced macrophage-preconditioning strategy for improved nanodelivery. Sci Rep. 2017;7(1):13738. https:\/\/doi.org\/10.1038\/s41598-017-14221-2.","journal-title":"Sci Rep"},{"issue":"7826","key":"965_CR76","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/s41586-020-2558-4","volume":"585","author":"P Maisonnasse","year":"2020","unstructured":"Maisonnasse P, Guedj J, Contreras V, Behillil S, Solas C, Marlin R, et al. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. Nature. 2020;585(7826):584\u20137. https:\/\/doi.org\/10.1038\/s41586-020-2558-4.","journal-title":"Nature"},{"issue":"11","key":"965_CR77","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/s1473-3099(03)00806-5","volume":"3","author":"A Savarino","year":"2003","unstructured":"Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today\u2019s diseases? Lancet Infect Dis. 2003;3(11):722\u20137. https:\/\/doi.org\/10.1016\/s1473-3099(03)00806-5.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"965_CR78","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1128\/AAC.01509-08","volume":"53","author":"E Keyaerts","year":"2009","unstructured":"Keyaerts E, Li S, Vijgen L, Rysman E, Verbeeck J, Van Ranst M, et al. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother. 2009;53(8):3416\u201321. https:\/\/doi.org\/10.1128\/AAC.01509-08.","journal-title":"Antimicrob Agents Chemother"},{"key":"965_CR79","doi-asserted-by":"publisher","unstructured":"Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv. 2020:2020.03.22.20040758. https:\/\/doi.org\/10.1101\/2020.03.22.20040758","DOI":"10.1101\/2020.03.22.20040758"},{"key":"965_CR80","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa623","author":"J Fan","year":"2020","unstructured":"Fan J, Zhang X, Liu J, Yang Y, Zheng N, Liu Q, et al. Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect: a critical step in treating COVID-19 patients. Clin Infect Dis. 2020. https:\/\/doi.org\/10.1093\/cid\/ciaa623.","journal-title":"Clin Infect Dis"},{"key":"965_CR81","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12923","author":"TT Tai","year":"2020","unstructured":"Tai TT, Wu TJ, Wu HD, Tsai YC, Wang HT, Wang AM, et al. A Strategy to treat COVID-19 disease with targeted delivery of inhalable liposomal hydroxychloroquine: a preclinical pharmacokinetic study. Clin Transl Sci. 2020. https:\/\/doi.org\/10.1111\/cts.12923.","journal-title":"Clin Transl Sci"},{"key":"965_CR82","doi-asserted-by":"publisher","first-page":"102099","DOI":"10.1016\/j.nano.2019.102099","volume":"22","author":"WL Fotoran","year":"2019","unstructured":"Fotoran WL, Muntefering T, Kleiber N, Miranda BNM, Liebau E, Irvine DJ, et al. A multilamellar nanoliposome stabilized by interlayer hydrogen bonds increases antimalarial drug efficacy. Nanomedicine. 2019;22:102099. https:\/\/doi.org\/10.1016\/j.nano.2019.102099.","journal-title":"Nanomedicine"},{"issue":"8","key":"965_CR83","doi-asserted-by":"publisher","first-page":"6884","DOI":"10.1021\/nn402062f","volume":"7","author":"LM Bimbo","year":"2013","unstructured":"Bimbo LM, Denisova OV, Makila E, Kaasalainen M, De Brabander JK, Hirvonen J, et al. Inhibition of influenza A virus infection in vitro by saliphenylhalamide-loaded porous silicon nanoparticles. ACS Nano. 2013;7(8):6884\u201393. https:\/\/doi.org\/10.1021\/nn402062f.","journal-title":"ACS Nano"},{"issue":"1","key":"965_CR84","doi-asserted-by":"publisher","first-page":"13043","DOI":"10.1038\/s41598-017-13316-0","volume":"7","author":"CJ Hu","year":"2017","unstructured":"Hu CJ, Chang WS, Fang ZS, Chen YT, Wang WL, Tsai HH, et al. Nanoparticulate vacuolar ATPase blocker exhibits potent host-targeted antiviral activity against feline coronavirus. Sci Rep. 2017;7(1):13043. https:\/\/doi.org\/10.1038\/s41598-017-13316-0.","journal-title":"Sci Rep"},{"issue":"3","key":"965_CR85","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.antiviral.2013.06.014","volume":"99","author":"HW Chen","year":"2013","unstructured":"Chen HW, Cheng JX, Liu MT, King K, Peng JY, Zhang XQ, et al. Inhibitory and combinatorial effect of diphyllin, a v-ATPase blocker, on influenza viruses. Antiviral Res. 2013;99(3):371\u201382. https:\/\/doi.org\/10.1016\/j.antiviral.2013.06.014.","journal-title":"Antiviral Res"},{"key":"965_CR86","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ebiom.2019.08.060","volume":"47","author":"A Martinez-Lopez","year":"2019","unstructured":"Martinez-Lopez A, Persaud M, Chavez MP, Zhang H, Rong L, Liu S, et al. Glycosylated diphyllin as a broad-spectrum antiviral agent against Zika virus. EBioMedicine. 2019;47:269\u201383. https:\/\/doi.org\/10.1016\/j.ebiom.2019.08.060.","journal-title":"EBioMedicine"},{"key":"965_CR87","doi-asserted-by":"publisher","DOI":"10.1111\/tbed.13856","author":"S Paltrinieri","year":"2020","unstructured":"Paltrinieri S, Giordano A, Stranieri A, Lauzi S. Feline infectious peritonitis (FIP) and coronavirus disease 19 (COVID-19): are they similar? Transbound Emerg Dis. 2020. https:\/\/doi.org\/10.1111\/tbed.13856.","journal-title":"Transbound Emerg Dis"},{"key":"965_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30511-7","author":"PD Monk","year":"2020","unstructured":"Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020. https:\/\/doi.org\/10.1016\/S2213-2600(20)30511-7.","journal-title":"Lancet Respir Med"},{"key":"965_CR89","doi-asserted-by":"publisher","unstructured":"Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515). doi:https:\/\/doi.org\/10.1126\/science.abd4570.","DOI":"10.1126\/science.abd4570"},{"key":"965_CR90","doi-asserted-by":"publisher","unstructured":"Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515). doi:https:\/\/doi.org\/10.1126\/science.abd4585.","DOI":"10.1126\/science.abd4585"},{"key":"965_CR91","doi-asserted-by":"publisher","DOI":"10.1201\/9780367801199","volume-title":"Pharmaceutical Biotechnology","author":"M Groves","year":"2005","unstructured":"Groves M. Pharmaceutical Biotechnology. 2nd ed. New York: Taylor & Francis Group; 2005.","edition":"2"},{"issue":"2","key":"965_CR92","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nri3787","volume":"15","author":"F McNab","year":"2015","unstructured":"McNab F, Mayer-Barber K, Sher A, Wack A, O\u2019Garra A. Type I interferons in infectious disease. Nat Rev Immunol. 2015;15(2):87\u2013103. https:\/\/doi.org\/10.1038\/nri3787.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"965_CR93","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nri1604","volume":"5","author":"LC Platanias","year":"2005","unstructured":"Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5(5):375\u201386. https:\/\/doi.org\/10.1038\/nri1604.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"965_CR94","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/nri3133","volume":"12","author":"JM Gonzalez-Navajas","year":"2012","unstructured":"Gonzalez-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol. 2012;12(2):125\u201335. https:\/\/doi.org\/10.1038\/nri3133.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"965_CR95","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.idc.2011.07.008","volume":"25","author":"SJ Bergman","year":"2011","unstructured":"Bergman SJ, Ferguson MC, Santanello C. Interferons as therapeutic agents for infectious diseases. Infect Dis Clin North Am. 2011;25(4):819\u201334. https:\/\/doi.org\/10.1016\/j.idc.2011.07.008.","journal-title":"Infect Dis Clin North Am"},{"key":"965_CR96","doi-asserted-by":"publisher","unstructured":"Prokunina-Olsson L, Alphonse N, Dickenson RE, Durbin JE, Glenn JS, Hartmann R et al. COVID-19 and emerging viral infections: the case for interferon lambda. J Exp Med. 2020;217(5). https:\/\/doi.org\/10.1084\/jem.20200653","DOI":"10.1084\/jem.20200653"},{"issue":"3\u20134","key":"965_CR97","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/s0928-0987(03)00019-8","volume":"18","author":"A S\u00e1nchez","year":"2003","unstructured":"S\u00e1nchez A, Tob\u0131\u0301o Ma, Gonz\u00e1lez L, Fabra A, Alonso MaJ. Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-alpha. Eur J Pharm Sci. 2003;18(3\u20134):221\u20139. https:\/\/doi.org\/10.1016\/s0928-0987(03)00019-8.","journal-title":"Eur J Pharm Sci"},{"issue":"1\u20132","key":"965_CR98","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/0378-5173(95)04227-x","volume":"128","author":"C Karau","year":"1996","unstructured":"Karau C, Petszulat M, Schmidt PC. Preparation and stability of interferon-\u03b1-containing liposomes. Int J Pharmaceut. 1996;128(1\u20132):89\u201398. https:\/\/doi.org\/10.1016\/0378-5173(95)04227-x.","journal-title":"Int J Pharmaceut"},{"issue":"11","key":"965_CR99","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1073\/pnas.82.11.3688","volume":"82","author":"DA Eppstein","year":"1985","unstructured":"Eppstein DA, Marsh YV, van der Pas M, Felgner PL, Schreiber AB. Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor. Proc Natl Acad Sci USA. 1985;82(11):3688\u201392. https:\/\/doi.org\/10.1073\/pnas.82.11.3688.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2\u20133","key":"965_CR100","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0166-3542(95)00832-2","volume":"29","author":"EG Saravolac","year":"1996","unstructured":"Saravolac EG, Kournikakis B, Gorton L, Wong JP. Effect of liposome-encapsulation on immunomodulating and antiviral activities of interferon-gamma 1. Antiviral Res. 1996;29(2\u20133):199\u2013207. https:\/\/doi.org\/10.1016\/0166-3542(95)00832-2.","journal-title":"Antiviral Res"},{"issue":"7213","key":"965_CR101","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nature07317","volume":"455","author":"H Ishikawa","year":"2008","unstructured":"Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature. 2008;455(7213):674\u20138. https:\/\/doi.org\/10.1038\/nature07317.","journal-title":"Nature"},{"key":"965_CR102","doi-asserted-by":"publisher","DOI":"10.2217\/nnm-2020-0269","author":"S Chattopadhyay","year":"2020","unstructured":"Chattopadhyay S, Hu CJ. Nanomedicinal delivery of stimulator of interferon genes agonists: recent advances in virus vaccination. Nanomedicine (Lond). 2020. https:\/\/doi.org\/10.2217\/nnm-2020-0269.","journal-title":"Nanomedicine (Lond)"},{"issue":"4","key":"965_CR103","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1021\/acs.nanolett.9b04094","volume":"20","author":"S Chattopadhyay","year":"2020","unstructured":"Chattopadhyay S, Liu YH, Fang ZS, Lin CL, Lin JC, Yao BY, et al. Synthetic immunogenic cell death mediated by intracellular delivery of STING agonist nanoshells enhances anticancer chemo-immunotherapy. Nano Lett. 2020;20(4):2246\u201356. https:\/\/doi.org\/10.1021\/acs.nanolett.9b04094.","journal-title":"Nano Lett"},{"issue":"28","key":"965_CR104","doi-asserted-by":"publisher","first-page":"1807616","DOI":"10.1002\/adfm.201807616","volume":"29","author":"LC Lin","year":"2019","unstructured":"Lin LC, Huang CY, Yao BY, Lin JC, Agrawal A, Algaissi A, et al. Viromimetic sting agonist-loaded hollow polymeric nanoparticles for safe and effective vaccination against Middle East respiratory syndrome coronavirus. Adv Funct Mater. 2019;29(28):1807616. https:\/\/doi.org\/10.1002\/adfm.201807616.","journal-title":"Adv Funct Mater"},{"key":"965_CR105","doi-asserted-by":"publisher","unstructured":"Wang J, Li P, Yu Y, Fu Y, Jiang H, Lu M et al. Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity. Science. 2020;367(6480). https:\/\/doi.org\/10.1126\/science.aau0810","DOI":"10.1126\/science.aau0810"},{"issue":"3","key":"965_CR106","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41565-018-0342-5","volume":"14","author":"D Shae","year":"2019","unstructured":"Shae D, Becker KW, Christov P, Yun DS, Lytton-Jean AKR, Sevimli S, et al. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. Nat Nanotechnol. 2019;14(3):269\u201378. https:\/\/doi.org\/10.1038\/s41565-018-0342-5.","journal-title":"Nat Nanotechnol"},{"issue":"7","key":"965_CR107","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/nnano.2017.52","volume":"12","author":"M Luo","year":"2017","unstructured":"Luo M, Wang H, Wang Z, Cai H, Lu Z, Li Y, et al. A STING-activating nanovaccine for cancer immunotherapy. Nat Nanotechnol. 2017;12(7):648\u201354. https:\/\/doi.org\/10.1038\/nnano.2017.52.","journal-title":"Nat Nanotechnol"},{"issue":"11","key":"965_CR108","doi-asserted-by":"publisher","first-page":"3840","DOI":"10.4049\/jimmunol.1700972","volume":"199","author":"C Aroh","year":"2017","unstructured":"Aroh C, Wang Z, Dobbs N, Luo M, Chen Z, Gao J, et al. Innate immune activation by cGMP-AMP nanoparticles leads to potent and long-acting antiretroviral response against HIV-1. J Immunol. 2017;199(11):3840\u20138. https:\/\/doi.org\/10.4049\/jimmunol.1700972.","journal-title":"J Immunol"},{"key":"965_CR109","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.2147\/IJN.S241492","volume":"15","author":"SY Lin","year":"2020","unstructured":"Lin SY, Yao BY, Hu CJ, Chen HW. Induction of robust immune responses by CpG-ODN-loaded hollow polymeric nanoparticles for antiviral and vaccine applications in chickens. Int J Nanomedicine. 2020;15:3303\u201318. https:\/\/doi.org\/10.2147\/IJN.S241492.","journal-title":"Int J Nanomedicine"},{"issue":"11","key":"965_CR110","first-page":"1582","volume":"43","author":"Z Yan","year":"2014","unstructured":"Yan Z, Li H, Chen F. Novel influenza A (H6N1) virus that infected a person in Taiwan. Iran J Public Health. 2014;43(11):1582\u20134.","journal-title":"Iran J Public Health"},{"key":"965_CR111","doi-asserted-by":"publisher","unstructured":"Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ, Ginn HM et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera. Cell. 2021. https:\/\/doi.org\/10.1016\/j.cell.2021.02.037","DOI":"10.1016\/j.cell.2021.02.037"},{"key":"965_CR112","doi-asserted-by":"publisher","unstructured":"Li Q, Nie J, Wu J, Zhang L, Ding R, Wang H et al. No higher infectivity but immune escape of SARS-CoV-2 501Y.V2 variants. Cell. 2021. https:\/\/doi.org\/10.1016\/j.cell.2021.02.042","DOI":"10.1016\/j.cell.2021.02.042"},{"issue":"6","key":"965_CR113","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.tibtech.2012.03.002","volume":"30","author":"DA Bricarello","year":"2012","unstructured":"Bricarello DA, Patel MA, Parikh AN. Inhibiting host\u2013pathogen interactions using membrane-based nanostructures. Trends Biotechnol. 2012;30(6):323\u201330. https:\/\/doi.org\/10.1016\/j.tibtech.2012.03.002.","journal-title":"Trends Biotechnol"},{"issue":"27","key":"965_CR114","doi-asserted-by":"publisher","first-page":"10980","DOI":"10.1073\/pnas.1106634108","volume":"108","author":"CM Hu","year":"2011","unstructured":"Hu CM, Zhang L, Aryal S, Cheung C, Fang RH, Zhang L. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci U S A. 2011;108(27):10980\u20135. https:\/\/doi.org\/10.1073\/pnas.1106634108.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"965_CR115","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/nnano.2013.254","volume":"8","author":"CM Hu","year":"2013","unstructured":"Hu CM, Fang RH, Luk BT, Zhang L. Nanoparticle-detained toxins for safe and effective vaccination. Nat Nanotechnol. 2013;8(12):933\u20138. https:\/\/doi.org\/10.1038\/nnano.2013.254.","journal-title":"Nat Nanotechnol"},{"issue":"26","key":"965_CR116","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1002\/adma.201300638","volume":"25","author":"W Gao","year":"2013","unstructured":"Gao W, Hu CM, Fang RH, Luk BT, Su J, Zhang L. Surface functionalization of gold nanoparticles with red blood cell membranes. Adv Mater. 2013;25(26):3549\u201353. https:\/\/doi.org\/10.1002\/adma.201300638.","journal-title":"Adv Mater"},{"issue":"5","key":"965_CR117","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1039\/c3nr06371b","volume":"6","author":"BT Luk","year":"2014","unstructured":"Luk BT, Hu CM, Fang RH, Dehaini D, Carpenter C, Gao W, et al. Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles. Nanoscale. 2014;6(5):2730\u20137. https:\/\/doi.org\/10.1039\/c3nr06371b.","journal-title":"Nanoscale"},{"issue":"46","key":"965_CR118","doi-asserted-by":"publisher","first-page":"6225","DOI":"10.1002\/smll.201502388","volume":"11","author":"L Rao","year":"2015","unstructured":"Rao L, Bu LL, Xu JH, Cai B, Yu GT, Yu X, et al. Red blood cell membrane as a biomimetic nanocoating for prolonged circulation time and reduced accelerated blood clearance. Small. 2015;11(46):6225\u201336. https:\/\/doi.org\/10.1002\/smll.201502388.","journal-title":"Small"},{"issue":"44","key":"965_CR119","doi-asserted-by":"publisher","first-page":"7043","DOI":"10.1002\/adma.201503323","volume":"27","author":"Q Hu","year":"2015","unstructured":"Hu Q, Sun W, Qian C, Wang C, Bomba HN, Gu Z. Anticancer platelet-mimicking nanovehicles. Adv Mater. 2015;27(44):7043\u201350. https:\/\/doi.org\/10.1002\/adma.201503323.","journal-title":"Adv Mater"},{"issue":"7571","key":"965_CR120","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nature15373","volume":"526","author":"CM Hu","year":"2015","unstructured":"Hu CM, Fang RH, Wang KC, Luk BT, Thamphiwatana S, Dehaini D, et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature. 2015;526(7571):118\u201321. https:\/\/doi.org\/10.1038\/nature15373.","journal-title":"Nature"},{"issue":"4","key":"965_CR121","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1021\/acs.nanolett.8b03913","volume":"19","author":"L Rao","year":"2019","unstructured":"Rao L, Wang W, Meng QF, Tian M, Cai B, Wang Y, et al. A Biomimetic nanodecoy traps Zika virus to prevent viral infection and fetal microcephaly development. Nano Lett. 2019;19(4):2215\u201322. https:\/\/doi.org\/10.1021\/acs.nanolett.8b03913.","journal-title":"Nano Lett"},{"issue":"45","key":"965_CR122","doi-asserted-by":"publisher","first-page":"E6129","DOI":"10.1073\/pnas.1505799112","volume":"112","author":"P Zhang","year":"2015","unstructured":"Zhang P, Chen Y, Zeng Y, Shen C, Li R, Guo Z, et al. Virus-mimetic nanovesicles as a versatile antigen-delivery system. Proc Natl Acad Sci U S A. 2015;112(45):E6129\u201338. https:\/\/doi.org\/10.1073\/pnas.1505799112.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"37","key":"965_CR123","doi-asserted-by":"publisher","first-page":"28403","DOI":"10.1074\/jbc.R110.129809","volume":"285","author":"SJ Gamblin","year":"2010","unstructured":"Gamblin SJ, Skehel JJ. Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem. 2010;285(37):28403\u20139. https:\/\/doi.org\/10.1074\/jbc.R110.129809.","journal-title":"J Biol Chem"},{"issue":"24","key":"965_CR124","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1002\/smll.201001349","volume":"6","author":"I Papp","year":"2010","unstructured":"Papp I, Sieben C, Ludwig K, Roskamp M, Bottcher C, Schlecht S, et al. Inhibition of influenza virus infection by multivalent sialic-acid-functionalized gold nanoparticles. Small. 2010;6(24):2900\u20136. https:\/\/doi.org\/10.1002\/smll.201001349.","journal-title":"Small"},{"issue":"5","key":"965_CR125","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1128\/JVI.02885-12","volume":"87","author":"H Zeng","year":"2013","unstructured":"Zeng H, Goldsmith CS, Maines TR, Belser JA, Gustin KM, Pekosz A, et al. Tropism and infectivity of influenza virus, including highly pathogenic avian H5N1 virus, in ferret tracheal differentiated primary epithelial cell cultures. J Virol. 2013;87(5):2597\u2013607. https:\/\/doi.org\/10.1128\/JVI.02885-12.","journal-title":"J Virol"},{"issue":"1","key":"965_CR126","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nnano.2016.181","volume":"12","author":"SJ Kwon","year":"2017","unstructured":"Kwon SJ, Na DH, Kwak JH, Douaisi M, Zhang F, Park EJ, et al. Nanostructured glycan architecture is important in the inhibition of influenza A virus infection. Nat Nanotechnol. 2017;12(1):48\u201354. https:\/\/doi.org\/10.1038\/nnano.2016.181.","journal-title":"Nat Nanotechnol"},{"issue":"46","key":"965_CR127","doi-asserted-by":"publisher","first-page":"39953","DOI":"10.1021\/acsami.7b09931","volume":"9","author":"HW Chen","year":"2017","unstructured":"Chen HW, Fang ZS, Chen YT, Chen YI, Yao BY, Cheng JY, et al. Targeting and enrichment of viral pathogen by cell membrane cloaked magnetic nanoparticles for enhanced detection. ACS Appl Mater Interfaces. 2017;9(46):39953\u201361. https:\/\/doi.org\/10.1021\/acsami.7b09931.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"7","key":"965_CR128","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1021\/acs.nanolett.0c01723","volume":"20","author":"C Nie","year":"2020","unstructured":"Nie C, Stadtmuller M, Yang H, Xia Y, Wolff T, Cheng C, et al. Spiky nanostructures with geometry-matching topography for virus inhibition. Nano Lett. 2020;20(7):5367\u201375. https:\/\/doi.org\/10.1021\/acs.nanolett.0c01723.","journal-title":"Nano Lett"},{"key":"965_CR129","doi-asserted-by":"publisher","unstructured":"Nie C, Stadtm\u00fcller M, Parshad B, Wallert M, Ahmadi V, Kerkhoff Y et al. Heteromultivalent topology-matched nanostructures as potent and broad-spectrum influenza A virus inhibitors. Science Advances. 2021;7(1). https:\/\/doi.org\/10.1126\/sciadv.abd3803","DOI":"10.1126\/sciadv.abd3803"},{"issue":"6605","key":"965_CR130","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/384184a0","volume":"384","author":"A Trkola","year":"1996","unstructured":"Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP, et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature. 1996;384(6605):184\u20137. https:\/\/doi.org\/10.1038\/384184a0.","journal-title":"Nature"},{"issue":"2","key":"965_CR131","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jconrel.2011.02.023","volume":"151","author":"T Bronshtein","year":"2011","unstructured":"Bronshtein T, Toledano N, Danino D, Pollack S, Machluf M. Cell derived liposomes expressing CCR5 as a new targeted drug-delivery system for HIV infected cells. J Control Release. 2011;151(2):139\u201348. https:\/\/doi.org\/10.1016\/j.jconrel.2011.02.023.","journal-title":"J Control Release"},{"issue":"11","key":"965_CR132","doi-asserted-by":"publisher","first-page":"e113691","DOI":"10.1371\/journal.pone.0113691","volume":"9","author":"JV de Carvalho","year":"2014","unstructured":"de Carvalho JV, de Castro RO, da Silva EZ, Silveira PP, da Silva-Januario ME, Arruda E, et al. Nef neutralizes the ability of exosomes from CD4+ T cells to act as decoys during HIV-1 infection. PLoS ONE. 2014;9(11):e113691. https:\/\/doi.org\/10.1371\/journal.pone.0113691.","journal-title":"PLoS ONE"},{"issue":"45","key":"965_CR133","doi-asserted-by":"publisher","first-page":"e1802233","DOI":"10.1002\/adma.201802233","volume":"30","author":"X Wei","year":"2018","unstructured":"Wei X, Zhang G, Ran D, Krishnan N, Fang RH, Gao W, et al. T-cell-mimicking nanoparticles can neutralize HIV infectivity. Adv Mater. 2018;30(45):e1802233. https:\/\/doi.org\/10.1002\/adma.201802233.","journal-title":"Adv Mater"},{"key":"965_CR134","doi-asserted-by":"publisher","unstructured":"Zhang G, Campbell GR, Zhang Q, Maule E, Hanna J, Gao W et al. CD4(+) T cell-mimicking nanoparticles broadly neutralize HIV-1 and suppress viral replication through autophagy. mBio. 2020;11(5). https:\/\/doi.org\/10.1128\/mBio.00903-20.","DOI":"10.1128\/mBio.00903-20"},{"issue":"10","key":"965_CR135","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1056\/NEJMoa1600651","volume":"374","author":"J Mlakar","year":"2016","unstructured":"Mlakar J, Korva M, Tul N, Popovic M, Poljsak-Prijatelj M, Mraz J, et al. Zika virus associated with microcephaly. N Engl J Med. 2016;374(10):951\u20138. https:\/\/doi.org\/10.1056\/NEJMoa1600651.","journal-title":"N Engl J Med"},{"issue":"16","key":"965_CR136","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1056\/NEJMra1602113","volume":"374","author":"LR Petersen","year":"2016","unstructured":"Petersen LR, Jamieson DJ, Powers AM, Honein MA. Zika Virus. N Engl J Med. 2016;374(16):1552\u201363. https:\/\/doi.org\/10.1056\/NEJMra1602113.","journal-title":"N Engl J Med"},{"key":"965_CR137","doi-asserted-by":"publisher","unstructured":"Lee I, Bos S, Li G, Wang S, Gadea G, Despres P et al. Probing molecular insights into Zika virus(-)host interactions. Viruses. 2018;10(5). https:\/\/doi.org\/10.3390\/v10050233","DOI":"10.3390\/v10050233"},{"issue":"7","key":"965_CR138","doi-asserted-by":"publisher","first-page":"5570","DOI":"10.1021\/acs.nanolett.0c02278","volume":"20","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Honko A, Zhou J, Gong H, Downs SN, Vasquez JH, et al. Cellular nanosponges inhibit SARS-CoV-2 infectivity. Nano Lett. 2020;20(7):5570\u20134. https:\/\/doi.org\/10.1021\/acs.nanolett.0c02278.","journal-title":"Nano Lett"},{"issue":"44","key":"965_CR139","doi-asserted-by":"publisher","first-page":"27141","DOI":"10.1073\/pnas.2014352117","volume":"117","author":"L Rao","year":"2020","unstructured":"Rao L, Xia S, Xu W, Tian R, Yu G, Gu C, et al. Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines. Proc Natl Acad Sci U S A. 2020;117(44):27141\u20137. https:\/\/doi.org\/10.1073\/pnas.2014352117.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"38","key":"965_CR140","doi-asserted-by":"publisher","first-page":"12499","DOI":"10.1002\/anie.201807212","volume":"57","author":"X Liu","year":"2018","unstructured":"Liu X, Yuan L, Zhang L, Mu Y, Li X, Liu C, et al. Bioinspired artificial nanodecoys for hepatitis B virus. Angew Chem Int Ed Engl. 2018;57(38):12499\u2013503. https:\/\/doi.org\/10.1002\/anie.201807212.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"43","key":"965_CR141","doi-asserted-by":"publisher","first-page":"11488","DOI":"10.1073\/pnas.1714267114","volume":"114","author":"S Thamphiwatana","year":"2017","unstructured":"Thamphiwatana S, Angsantikul P, Escajadillo T, Zhang Q, Olson J, Luk BT, et al. Macrophage-like nanoparticles concurrently absorbing endotoxins and proinflammatory cytokines for sepsis management. Proc Natl Acad Sci USA. 2017;114(43):11488\u201393. https:\/\/doi.org\/10.1073\/pnas.1714267114.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"965_CR142","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","volume":"384","author":"AC Kalil","year":"2021","unstructured":"Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New Engl J Med. 2021;384(9):795\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa2031994.","journal-title":"New Engl J Med"},{"issue":"48","key":"965_CR143","doi-asserted-by":"publisher","first-page":"28434","DOI":"10.1039\/d0cp04389c","volume":"22","author":"J Wu","year":"2020","unstructured":"Wu J, Wang H, Li B. Structure-aided ACEI-capped remdesivir-loaded novel PLGA nanoparticles: toward a computational simulation design for anti-SARS-CoV-2 therapy. Phys Chem Chem Phys. 2020;22(48):28434\u20139. https:\/\/doi.org\/10.1039\/d0cp04389c.","journal-title":"Phys Chem Chem Phys"},{"issue":"4","key":"965_CR144","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jsps.2019.01.012","volume":"27","author":"MJ Ansari","year":"2019","unstructured":"Ansari MJ, Alshahrani SM. Nano-encapsulation and characterization of baricitinib using poly-lactic-glycolic acid co-polymer. Saudi Pharmaceutical Journal. 2019;27(4):491\u2013501. https:\/\/doi.org\/10.1016\/j.jsps.2019.01.012.","journal-title":"Saudi Pharmaceutical Journal"},{"issue":"1","key":"965_CR145","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2016.108","volume":"17","author":"J Shi","year":"2017","unstructured":"Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20\u201337. https:\/\/doi.org\/10.1038\/nrc.2016.108.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"965_CR146","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/ncponc0036","volume":"1","author":"VT DeVita Jr","year":"2004","unstructured":"DeVita VT Jr. The \u2018war on cancer\u2019 and its impact. Nat Clin Pract Oncol. 2004;1(2):55. https:\/\/doi.org\/10.1038\/ncponc0036.","journal-title":"Nat Clin Pract Oncol"},{"issue":"5","key":"965_CR147","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/wnan.98","volume":"2","author":"K Ptak","year":"2010","unstructured":"Ptak K, Farrell D, Panaro NJ, Grodzinski P, Barker AD. The NCI Alliance for Nanotechnology in Cancer: achievement and path forward. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010;2(5):450\u201360. https:\/\/doi.org\/10.1002\/wnan.98.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"issue":"9","key":"965_CR148","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1021\/acs.accounts.9b00228","volume":"52","author":"H He","year":"2019","unstructured":"He H, Liu L, Morin EE, Liu M, Schwendeman A. Survey of clinical translation of cancer nanomedicines\u2014lessons learned from successes and failures. Acc Chem Res. 2019;52(9):2445\u201361. https:\/\/doi.org\/10.1021\/acs.accounts.9b00228.","journal-title":"Acc Chem Res"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-021-00965-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-021-00965-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-021-00965-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T20:47:35Z","timestamp":1624740455000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-021-00965-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,21]]},"references-count":148,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["965"],"URL":"https:\/\/doi.org\/10.1007\/s13346-021-00965-y","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,21]]},"assertion":[{"value":"11 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consent for publication has been acquired from original publishers for the cited figures in the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}